326 related articles for article (PubMed ID: 31366221)
1. Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries.
Ohlsson L; Haanes KA; Kronvall E; Xu C; Snellman J; Edvinsson L
Cephalalgia; 2019 Dec; 39(14):1745-1752. PubMed ID: 31366221
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries.
Rubio-Beltrán E; Labastida-Ramírez A; Haanes KA; van den Bogaerdt A; Bogers AJ; Dirven C; Danser AJ; Xu C; Snellman J; MaassenVanDenBrink A
Cephalalgia; 2019 Dec; 39(14):1735-1744. PubMed ID: 31284729
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries.
Rubio-Beltran E; Chan KY; Danser AJ; MaassenVanDenBrink A; Edvinsson L
Cephalalgia; 2020 Apr; 40(4):357-366. PubMed ID: 31674221
[TBL] [Abstract][Full Text] [Related]
4. Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries.
Ohlsson L; Kronvall E; Stratton J; Edvinsson L
J Headache Pain; 2018 Aug; 19(1):66. PubMed ID: 30109438
[TBL] [Abstract][Full Text] [Related]
5. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries.
Jansen I; Uddman R; Ekman R; Olesen J; Ottosson A; Edvinsson L
Peptides; 1992; 13(3):527-36. PubMed ID: 1381830
[TBL] [Abstract][Full Text] [Related]
6. Erenumab: First Global Approval.
Markham A
Drugs; 2018 Jul; 78(11):1157-1161. PubMed ID: 29968151
[TBL] [Abstract][Full Text] [Related]
7. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
Mullin K; Kudrow D; Croop R; Lovegren M; Conway CM; Coric V; Lipton RB
Neurology; 2020 May; 94(20):e2121-e2125. PubMed ID: 31932515
[TBL] [Abstract][Full Text] [Related]
8. Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention.
Rozen TD; Bhatt AA
Cephalalgia; 2022 Mar; 42(3):250-256. PubMed ID: 34405713
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of CGRP receptors in the human isolated middle meningeal artery.
Gupta S; Mehrotra S; Avezaat CJ; Villalón CM; Saxena PR; Maassenvandenbrink A
Life Sci; 2006 Jun; 79(3):265-71. PubMed ID: 16458930
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment.
Moreno MJ; Abounader R; Hébert E; Doods H; Hamel E
Neuropharmacology; 2002 Mar; 42(4):568-76. PubMed ID: 11955527
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors.
Garelja ML; Alexander TI; Bennie A; Nimick M; Petersen J; Walker CS; Hay DL
Br J Pharmacol; 2024 Jan; 181(1):142-161. PubMed ID: 37580864
[TBL] [Abstract][Full Text] [Related]
12. Erenumab in the treatment of migraine.
Jain S; Yuan H; Spare N; Silberstein SD
Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
[TBL] [Abstract][Full Text] [Related]
13. Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction.
Grell AS; Haanes KA; Johansson SE; Edvinsson L; Sams A
Eur J Pharmacol; 2019 Dec; 864():172726. PubMed ID: 31589869
[TBL] [Abstract][Full Text] [Related]
14. Neurogenic vasodilation in rabbit basilar isolated artery: involvement of calcitonin-gene related peptide.
Olivar T; Razzaque Z; Nwagwu M; Longmore J
Eur J Pharmacol; 2000 Apr; 395(1):61-8. PubMed ID: 10781675
[TBL] [Abstract][Full Text] [Related]
15. Cardio- and cerebrovascular safety of erenumab, a monoclonal antibody targeting CGRP receptors - important studies on human isolated arteries.
Messlinger K; MaassenVanDenBrink A
Cephalalgia; 2019 Dec; 39(14):1731-1734. PubMed ID: 31526030
[No Abstract] [Full Text] [Related]
16. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
17. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
Garland SG; Smith SM; Gums JG
Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
[No Abstract] [Full Text] [Related]
18. In-depth characterization of CGRP receptors in human intracranial arteries.
Jansen-Olesen I; Jørgensen L; Engel U; Edvinsson L
Eur J Pharmacol; 2003 Nov; 481(2-3):207-16. PubMed ID: 14642788
[TBL] [Abstract][Full Text] [Related]
19. Limitations in using peptide drugs to characterize calcitonin gene-related peptide receptors.
Waugh DJ; Bockman CS; Smith DD; Abel PW
J Pharmacol Exp Ther; 1999 Jun; 289(3):1419-26. PubMed ID: 10336535
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine.
Bussiere JL; Davies R; Dean C; Xu C; Kim KH; Vargas HM; Chellman GJ; Balasubramanian G; Rubio-Beltran E; MaassenVanDenBrink A; Monticello TM
Regul Toxicol Pharmacol; 2019 Aug; 106():224-238. PubMed ID: 31085251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
